Dexcom raised its annual revenue outlook and announced a share-repurchase authorization of up to $1 billion on October 29.
The glucose-monitoring company now expects 2026 revenue of $5.20 billion to $5.25 billion, representing approximately 12%–13% growth. It also increased its adjusted operating-margin forecast to approximately 24%.
Third-quarter revenue rose 11% from a year earlier to $1.344 billion. U.S. revenue increased 14%, while international revenue grew 5%.
GAAP operating income reached $327.2 million, or 24.3% of revenue, compared with $242.5 million, or 20.1%, a year earlier.
GAAP net income moved in the opposite direction, declining to $275.1 million from $283.8 million. Diluted earnings increased to 72 cents per share from 70 cents.
Adjusted net income was $275 million, or 73 cents per diluted share. Those adjusted results exclude specified items included in GAAP figures.
Dexcom held $1.82 billion in cash, cash equivalents and marketable securities at September 30, with its revolving credit facility undrawn.
The annual outlook remains a forecast. The buyback authorization permits future purchases and does not establish that the full amount has been spent.
Sources: Dexcom — October 29 Results via Business Wire: https://www.stocktitan.net/news/DXCM/dexcom-reports-third-quarter-2026-financial-1syfpa94iw1d.html